JP4472346B2 - ベータ−ラクタマーゼの阻害剤として活性である新規な複素環化合物 - Google Patents

ベータ−ラクタマーゼの阻害剤として活性である新規な複素環化合物 Download PDF

Info

Publication number
JP4472346B2
JP4472346B2 JP2003563554A JP2003563554A JP4472346B2 JP 4472346 B2 JP4472346 B2 JP 4472346B2 JP 2003563554 A JP2003563554 A JP 2003563554A JP 2003563554 A JP2003563554 A JP 2003563554A JP 4472346 B2 JP4472346 B2 JP 4472346B2
Authority
JP
Japan
Prior art keywords
oxo
octane
trans
diazabicyclo
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003563554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523897A (ja
Inventor
ジョゼフ・アソーディ
クロード・フロマンタン
マクシム・ラムピラ
デイヴィッド・アラン・ロウランズ
Original Assignee
ノヴェクセル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4472346(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノヴェクセル filed Critical ノヴェクセル
Publication of JP2005523897A publication Critical patent/JP2005523897A/ja
Application granted granted Critical
Publication of JP4472346B2 publication Critical patent/JP4472346B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003563554A 2002-01-28 2003-01-27 ベータ−ラクタマーゼの阻害剤として活性である新規な複素環化合物 Expired - Lifetime JP4472346B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
PCT/FR2003/000243 WO2003063864A2 (fr) 2002-01-28 2003-01-27 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Publications (2)

Publication Number Publication Date
JP2005523897A JP2005523897A (ja) 2005-08-11
JP4472346B2 true JP4472346B2 (ja) 2010-06-02

Family

ID=27619669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003563554A Expired - Lifetime JP4472346B2 (ja) 2002-01-28 2003-01-27 ベータ−ラクタマーゼの阻害剤として活性である新規な複素環化合物

Country Status (44)

Country Link
US (4) US7612087B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2279737B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4472346B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100979079B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN100482225C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR038234A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE484281T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003214335B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2016C069I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0307267B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2474043C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2011000009A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5601014A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (2) CR7387A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (3) CY1111061T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60334527D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1480644T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA007220B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP045193A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2401855T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (2) FR2835186B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20040686B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUS1600055I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL163167A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JO (1) JO2646B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1480644I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA26351A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04006621A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY140638A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300847I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO335195B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ533936A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA12761A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20030969A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL220725B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT1480644E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS52137B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI1480644T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN (1) TNSN04137A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI293071B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA80271C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY27626A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2003063864A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200405607B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
WO2007063552A1 (en) * 2005-12-02 2007-06-07 Lupin Limited Stable taste masked formulations of cephalosporins
DK2308874T3 (da) 2005-12-07 2013-04-15 Basilea Pharmaceutica Ag Brokoblede monobactamer nyttige som beta-lactamase-inhibitorer
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
JP2010507681A (ja) * 2006-10-23 2010-03-11 アイアールエム・リミテッド・ライアビリティ・カンパニー カテプシンプロテアーゼ阻害剤
US8563732B2 (en) * 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
PT2666774E (pt) * 2008-01-18 2015-04-13 Merck Sharp & Dohme Inibidores de beta-lactamase
WO2009114921A1 (en) * 2008-03-17 2009-09-24 Dmitrienko Gary I INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
JP5501983B2 (ja) * 2008-06-11 2014-05-28 塩野義製薬株式会社 オキシカルバモイル化合物およびその使用
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
NZ607354A (en) 2010-08-10 2015-01-30 Rempex Pharmaceuticals Inc Cyclic boronic acid ester derivatives and therapeutic uses thereof
SG191320A1 (en) * 2010-12-22 2013-07-31 Meiji Seika Pharma Co Ltd Optically-active diazabicyclooctane derivative and method for manufacturing same
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
RU2610091C2 (ru) * 2011-06-17 2017-02-07 Астразенека Аб (2S,5R)-5-[(бензилокси)амино]пиперидин-2-карбоксамид
CN103619843B (zh) * 2011-08-27 2017-01-11 沃克哈特有限公司 1，6‑二氮杂双环[3，2，1]辛‑7‑酮衍生物及其在治疗细菌感染中的用途
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
EP3052497B1 (en) * 2011-09-13 2017-06-28 Wockhardt Limited Nitrogen containing compounds and their use
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8933233B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
MX2014011825A (es) 2012-03-30 2015-02-20 Cubist Pharm Inc INHIBIDORES DE ISOXAZOL ß-LACTAMASA.
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2857401B8 (en) 2012-05-30 2019-11-20 Meiji Seika Pharma Co., Ltd. NOVEL ß-LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CA2881169C (en) * 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104994844A (zh) 2013-01-04 2015-10-21 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
WO2014107536A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2970338A1 (en) 2013-03-14 2016-01-20 Merck Sharp & Dohme Corp. Crystalline form of a beta-lactamase inhibitor
EP3050883B1 (en) 2013-09-24 2020-04-22 Meiji Seika Pharma Co., Ltd. Production method for diazabicyclooctane derivatives and intermediates
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
EP3107539A1 (en) * 2014-02-20 2016-12-28 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
ES2985626T3 (es) 2014-05-05 2024-11-06 Melinta Therapeutics Inc Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
CA2947041A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081452A1 (en) * 2014-11-17 2016-05-26 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
SG11201704576SA (en) 2014-12-05 2017-07-28 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR102713561B1 (ko) * 2015-05-07 2024-10-08 무타빌리스 헤테로사이클릭 화합물 및 세균성 감염을 예방 또는 치료하는 이의 용도
US10167283B2 (en) 2015-09-16 2019-01-01 Suanzhu Pharma Co., Ltd. β-lactamase inhibitors and uses thereof
EP3356357A4 (en) 2015-10-02 2019-02-20 LegoChem Biosciences, Inc. COMPOSITIONS AND METHODS OF INHIBITING BETA LACTAMASE
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
EP3156400B1 (en) 2016-05-27 2019-05-15 Valoralia I Más D, SL Dihydrooxadiazine compounds for treating infections and cancer
EP3478693B1 (en) 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
EP3512851B1 (en) 2016-09-16 2022-07-06 Entasis Therapeutics Limited Beta-lactamase inhibitor compounds
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
RU2019124705A (ru) 2017-02-06 2021-02-05 Мутабилис Новые гетероциклические соединения и их применение в профилактике или лечении бактериальных инфекций
HRP20220231T1 (hr) 2017-05-08 2022-04-29 Entasis Therapeutics, Inc. Spojevi i postupci za liječenje bakterijskih infekcija
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited PROCESS FOR O-SULFONATION OF 1,6-DIAZABICYCLO [3.2.1] OCTANE COMPOUNDS
KR102626967B1 (ko) 2017-10-11 2024-01-18 큐펙스 바이오파마 인코포레이티드 보론산 유도체 및 이의 합성
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
WO2019093450A1 (ja) * 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
JP7329260B2 (ja) 2018-04-20 2023-08-18 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
TWI764030B (zh) 2018-08-09 2022-05-11 法商安塔比奧公司 化合物
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
US20230365561A1 (en) * 2020-09-01 2023-11-16 Ningxia Academy Of Agricul Ture And Forestry Sciences Beta-lactamase inhibitors and their preparation
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
WO2022233181A1 (en) 2021-05-07 2022-11-10 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
KR20240041506A (ko) 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법
CN116375706B (zh) * 2023-02-22 2025-02-14 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
DE69016430T2 (de) 1989-06-09 1995-06-01 Upjohn Co Heterozyklische amine mit zns-wirksamkeit.
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
AU7844594A (en) 1993-09-29 1995-04-18 Barry Burns Ring-expanded nucleosides and nucleotides
JP2895630B2 (ja) * 1993-12-29 1999-05-24 フアイザー・インコーポレイテツド ジアザビシクロニューロキニンアンタゴニスト
EP0702004A2 (de) 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
ES2205072T3 (es) * 1996-01-03 2004-05-01 Smithkline Beecham Plc Derivados carbamoiloxi de mutilina y su uso como agentes antibacterianos.
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
CA2327695A1 (en) 1998-04-08 1999-10-21 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
WO2000000479A1 (en) 1998-06-30 2000-01-06 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
ES2237963T3 (es) 1998-12-18 2005-08-01 Schering Corporation Inhibidores de farnesil proteina transferasa.
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
EP1227090A4 (en) 1999-10-07 2002-11-20 Tadeka Chemical Ind Ltd AMINE DERIVATIVES
US20030105118A1 (en) 2000-04-18 2003-06-05 Shuji Masumoto Tricyclic quinazolinediones
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
US7179921B2 (en) 2001-02-22 2007-02-20 School Of Pharmacy, University Of London Indoline and tetrahydro-quinolines as prodrugs for tumour treatment
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
TNSN04137A1 (fr) 2007-03-12
CL2011000009A1 (es) 2011-03-25
FR2835186B1 (fr) 2006-10-20
NO2025027I1 (no) 2025-06-13
NZ533936A (en) 2007-05-31
BRPI0307267B8 (pt) 2021-05-25
NO20043587L (no) 2004-08-27
NO2016024I2 (no) 2016-12-15
NO2016024I1 (no) 2016-12-15
MA26351A1 (fr) 2004-10-01
ECSP045193A (es) 2004-08-27
DE60334527D1 (de) 2010-11-25
CN1655781A (zh) 2005-08-17
CN101406471A (zh) 2009-04-15
CY1111061T1 (el) 2015-06-11
UA80271C2 (uk) 2007-09-10
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
MY140638A (en) 2010-01-15
EA200400981A1 (ru) 2005-02-24
IL163167A (en) 2010-04-15
HUS1600055I1 (hu) 2017-01-30
CY1114417T1 (el) 2016-08-31
FR16C1019I2 (fr) 2017-12-29
RS52137B (en) 2012-08-31
PL220725B1 (pl) 2015-12-31
HK1077205A1 (zh) 2006-02-10
PL371601A1 (pl) 2005-06-27
OA12761A (fr) 2006-07-04
ZA200405607B (en) 2005-09-28
NO335195B1 (no) 2014-10-20
KR20040081473A (ko) 2004-09-21
BR0307267A (pt) 2004-12-07
HRP20040686B1 (hr) 2013-02-28
MXPA04006621A (es) 2004-10-04
CO5601014A2 (es) 2006-01-31
EA007220B1 (ru) 2006-08-25
TWI293071B (en) 2008-02-01
CY2016042I1 (el) 2017-03-15
CN100563653C (zh) 2009-12-02
ES2401855T3 (es) 2013-04-25
CN1994301A (zh) 2007-07-11
CR7387A (es) 2010-10-25
PT2279737E (pt) 2013-02-01
ATE484281T1 (de) 2010-10-15
SI1480644T1 (sl) 2011-03-31
YU65804A (sh) 2006-08-17
ES2356813T3 (es) 2011-04-13
WO2003063864A3 (fr) 2004-03-11
AU2003214335B2 (en) 2007-04-05
HK1105864A1 (zh) 2008-02-29
US20050020572A1 (en) 2005-01-27
US20100048528A1 (en) 2010-02-25
HRP20040686A2 (en) 2004-12-31
CN100482225C (zh) 2009-04-29
DK1480644T3 (da) 2011-01-24
BE2016C069I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-05-17
EP1480644B1 (fr) 2010-10-13
US20090215747A1 (en) 2009-08-27
CR20120356A (es) 2012-10-05
EP1480644A2 (fr) 2004-12-01
FR16C1019I1 (fr) 2017-02-03
AR100790A2 (es) 2016-11-02
WO2003063864A2 (fr) 2003-08-07
CA2474043A1 (fr) 2003-08-07
LTC1480644I2 (lt) 2018-09-10
US20110245254A1 (en) 2011-10-06
PT1480644E (pt) 2011-01-17
DK2279737T3 (da) 2013-02-11
US7612087B2 (en) 2009-11-03
EP2279737B1 (fr) 2012-10-31
SI2279737T1 (sl) 2013-07-31
NL300847I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-01-03
LTPA2016037I1 (lt) 2017-01-10
EP2279737A1 (fr) 2011-02-02
JP2005523897A (ja) 2005-08-11
FR2835186A1 (fr) 2003-08-01
BRPI0307267B1 (pt) 2016-02-10
JO2646B1 (en) 2012-06-17
CY2016042I2 (el) 2017-03-15
KR100979079B1 (ko) 2010-08-31
UY27626A1 (es) 2003-08-29
CA2474043C (fr) 2011-08-02
AR038234A1 (es) 2005-01-05

Similar Documents

Publication Publication Date Title
JP4472346B2 (ja) ベータ−ラクタマーゼの阻害剤として活性である新規な複素環化合物
JP4515704B2 (ja) 新規な複素環式化合物、それらの製造法及びそれらの薬剤、特に抗菌剤としての使用
US8148540B2 (en) Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents
BR122015020406B1 (pt) uso de compostos de formula i como inibidores de beta-lactamases e composições farmaceuticas
HK1077205B (en) Novel heterocyclic compounds which are active as inhibitors of beta+lactamases
HK1105864B (en) Heterocyclic compounds which are active as inhibitors of beta-lactamases

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051108

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090821

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090821

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090828

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100209

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100303

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130312

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4472346

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140312

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term